StockData
Pharvaris N.V. logo

Pharvaris N.V. (PHVS) stock

PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Apr 2, 2026Score 4/30
$32.28−0.16 (-0.49%)

Close on Nov 17, 2026Market cap $2.11BP/E –Yield –

Pharvaris operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -€173.71M. The highest annual figure on record is -€4.31M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€173.71M–
FY2024Dec 31, 2024-€132.40M–
FY2023Dec 31, 2023-€99.83M–
FY2022Dec 31, 2022-€75.65M–
FY2021Dec 31, 2021-€42.66M–
FY2020Dec 31, 2020-€26.07M–
FY2019Dec 31, 2019-€8.03M–
FY2018Dec 31, 2018-€4.31M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€47.24M–
Q2 FY2025Jun 30, 2025-€45.28M–
Q2 FY2024Jun 30, 2024-€29.66M–
Q2 FY2023Jun 30, 2023-€21.80M–
Q2 FY2022Jun 30, 2022-€9.88M–
Q2 FY2021Jun 30, 2021-€15.20M–

More Pharvaris figures

See a number that looks wrong?